Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

Will Dixon, Alan Silman

    Research output: Contribution to journalArticlepeer-review

    Abstract

    A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. © 2006 BioMed Central Ltd.
    Original languageEnglish
    Article number111
    JournalArthritis Research and Therapy
    Volume8
    Issue number5
    DOIs
    Publication statusPublished - Oct 2006

    Fingerprint

    Dive into the research topics of 'Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al'. Together they form a unique fingerprint.

    Cite this